Literature DB >> 3431264

[Hiatal hernia and reflux disease--long-term results following fundoplication and consequences in therapeutic failures].

C Ackermann1, L Margreth, C Muller, F Harder.   

Abstract

UNLABELLED: 10 to 20 years (median 15.1 years) after fundoplication for primary reflux disease 257 patients were questioned about their symptoms. Data of 163 patients could be analyzed.
RESULTS: 21.4% of the patients have persistent or recurrent reflux symptoms, about half of them (9.8%) need medical treatment. Adverse side-effects of the fundoplication are frequent: dysphagia in 28.2%, gas-bloat in 50.3%. Using the Visick criteria for classification we found Visick grade I and II for 75.5%, grade III for 17.2%, and IV for 7.4%. Diagnostic and therapeutic concepts in case of failed reflux control are discussed.

Entities:  

Mesh:

Year:  1987        PMID: 3431264     DOI: 10.1007/BF01297879

Source DB:  PubMed          Journal:  Langenbecks Arch Chir        ISSN: 0023-8236


  5 in total

1.  Post-fundoplication symptoms. Do they restrict the success of Nissen fundoplication?

Authors:  J B Negre
Journal:  Ann Surg       Date:  1983-12       Impact factor: 12.969

2.  [Reinterventions following reflux surgery].

Authors:  J R Siewert; H F Weiser
Journal:  Chirurg       Date:  1984-06       Impact factor: 0.955

3.  [Postoperative syndromes after surgery for termination of esophageal reflux (author's transl)].

Authors:  J Witte; G Feifel
Journal:  Leber Magen Darm       Date:  1982-04

4.  Randomized prospective trial of Roux-en-Y duodenal diversion versus fundoplication for severe reflux oesophagitis.

Authors:  G F Washer; M W Gear; B L Dowling; E W Gillison; C M Royston; J Spencer
Journal:  Br J Surg       Date:  1984-03       Impact factor: 6.939

5.  Partial gastrectomy with Roux-en-Y reconstruction in the treatment of persistent or recurrent oesophagitis after Nissen fundoplication.

Authors:  J A Salo; M Lempinen; E Kivilaakso
Journal:  Br J Surg       Date:  1985-08       Impact factor: 6.939

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.